logo-loader
NASDAQ:ALNY

Alnylam Pharmaceuticals

Receive alerts
Market:
NASDAQ
Market Cap:
$12.68 billion
Price
112.14 USD
Change
5.97%
52 weeks high
134.51
52 weeks low
65.81

In brief

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). The RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection.